Genmab — Februar 2021
-
Factors influencing response to talquetamab in myeloma https://www.youtube.com/watch?v=BeUaENS8204&feature=youtu.be (
not sure if it was posted before) -
Almost E L
-
Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline https://endpts.com/all-in-on-ide-cel-bristol-myers-squibb-writes-off-470m-for-dropping-a-second-bcma-car-t/
-
I never see it as good news when a cancer drug fails
-
But its still good to be updated. So thanks
for that EL -
Er det ikke kernen i markedsøkonomi. BMS kan bruge pengene bedre et andet sted.
-
Set ud fra en investorvinkel: Good news!!! Set ud fra en kræftbehandlingsvinkel: faktisk også good news, da pengene i udviklingsafdelingen vurderes brugt bedre på andre kandidater. Vi kan sagtens diskutere det fordnuftige i BMS's prioritering af deres udviklingsmidler, men fuldt bevidst at indtage en anden synsvinkel for at bashe en udmelding skrevet klart ud fra investorvinklen, endda med smiley, helt ærligt, troldmanden...
-
-
15.59 Læs lige hvem der kommenterer hvad, før du basher en med-Proinvestor, helt ærligt.
-
Opti, eftersom der klart refereres til "good news" fra Legolas 12.28 i det direkte efterfølgende indlæg fra troldmanden 14.08, så er jeg egentlig ikke i tvivl. Og det skal lige være sagt - jeg værdsætter faktisk troldmands saglige indlæg i diskutionerne, selv om jeg absolut ikke altid er enig. Men, hvis man udskammer nogen for at skrive ud fra en investorsynsvinkel i et investorforum, så er det altså ikke det rigtige forum, man har postet i.
-
Ok DevOp. jeg læste det som en irettesættelse af 12.28 kommentaren, men som om du mente at det var troldmand der skrev den. God fredag aften herfra.
-
Tusinde tak for opbakningen. Støtteabonnemnter kan tegnes her for små penge: https://www.proinvestor.com/donation
-
God morgen.
-
Faldt over denne gamle: In May 2017, Lonza Sales AG (Lonza) filed a Request for Arbitration with the London Court of International Arbitration against Janssen Research & Development, LLC (Janssen R&D). Lonza alleges that Janssen R&D breached a 2005 agreement between the parties by sublicensing certain Lonza technology used in the manufacture of daratumumab without Lonza’s consent. Lonza seeks monetary damages. In May 2019, the arbitration award was issued and the matter has been resolved
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind